ALPS Medical Breakthroughs ETF (SBIO)

Assets	$148.98M
Expense Ratio	0.50%
PE Ratio	n/a
Shares Out	2.93M
Dividend (ttm)	n/a
Dividend Yield	n/a
Ex-Dividend Date	n/a
Payout Frequency	n/a
Payout Ratio	n/a

Volume	15,950
Open	50.75
Previous Close	50.52
Day's Range	50.45 - 52.32
52-Week Low	29.33
52-Week High	57.77
Beta	0.77
Holdings	86
Inception Date	Dec 31, 2014

About SBIO

Fund Home Page

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is issued by SS&C.

• Asset Class: Equity
• Category: Health
• Region: North America
• Stock Exchange: NYSEARCA
• Ticker Symbol: SBIO
• ETF Provider: SS&C
• Index Tracked: S-Network Medical Breakthroughs Index

Top 10 Holdings

34.84% of assets

Name	Symbol	Weight
Alkermes plc	ALKS	5.01%
Kymera Therapeutics, Inc.	KYMR	4.38%
Spyre Therapeutics, Inc.	SYRE	4.04%
Mirum Pharmaceuticals, Inc.	MIRM	3.89%
CG Oncology, Inc.	CGON	3.18%
Apogee Therapeutics, Inc.	APGE	3.17%
Travere Therapeutics, Inc.	TVTX	2.96%
Xenon Pharmaceuticals Inc.	XENE	2.93%
Celcuity Inc.	CELC	2.80%
ACADIA Pharmaceuticals Inc.	ACAD	2.48%

Dividend History

Ex-Dividend	Amount	Pay Date
Dec 19, 2024	$1.17346	Dec 26, 2024
Dec 21, 2023	$0.07106	Dec 27, 2023
Dec 19, 2019	$0.01585	Dec 27, 2019
Dec 20, 2018	$0.7841	Dec 27, 2018
Dec 21, 2017	$0.57949	Dec 28, 2017

Performance

SBIO had a total return of 64.01% in the past year, including dividends. Since the fund's inception, the average annual return has been 7.31%.